Spark Therapeutics’ Hemophilia Gene Therapy Shows Reduction In Bleeding Episodes
Spark Therapeutics, a unit of Roche Holdings AG (OTC:RHHBY), has announced data from its Phase 1/2 trial of SPK-8011 in hemophilia A. …
Europe Approves Regeneron – Roche’s COVID-19 Antibody Cocktail
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve…
Hit By Slow Rollout, Biogen’s Aduhelm Could Soon Find Itself In Price Competition: Reuters
With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition.
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
ALX Oncology Holdings Inc (NASDAQ:ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort…
Regeneron-Roche’s COVID-19 Treatment Shows Long Term Benefit After Single Dose
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200…
Will Pfizer Outgun Merck With Oral COVID-19 Pill?
Merck, Inc. (NYSE: MRK) is locking horns with peer Pfizer, Inc. (NYSE: PFE) in what could be termed as the battle supremacy in the COVID-19 treatment market.
Novartis To Offload Its Stake Back To Roche For $20.7B
Novartis AG (NYSE:NVS), a shareholder in Roche Holdings AG (OTC:RHHBY) for more than 20 years, would sell its entire stake, which is…
Novartis, Roche Agreed on Bilateral Transaction for the Sale of Roche Bearer Shares Held by Novartis for $20.7B
Novartis has agreed to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a total consideration of USD 20.7 billion.
Galecto To Test GB1211 Combined with Roche’s Tecentriq In First Line Lung Cancer Setting
Galecto Inc (NASDAQ:GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC:RHHBY) to explore the combination of GB1211 in…
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck’s Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.